Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01369355
Registration number
NCT01369355
Ethics application status
Date submitted
7/06/2011
Date registered
8/06/2011
Date last updated
22/10/2020
Titles & IDs
Public title
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease
Query!
Secondary ID [1]
0
0
CNTO1275CRD3003
Query!
Secondary ID [2]
0
0
CR018421
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Colitis
0
0
Query!
IBD
0
0
Query!
Inflammatory Bowel Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo SC
Treatment: Drugs - Placebo IV
Treatment: Drugs - Ustekinumab 90 mg SC q8w
Treatment: Drugs - Ustekinumab 130 mg IV
Treatment: Drugs - Ustekinumab 90 mg SC q12w
Placebo comparator: 001 - Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
Experimental: 002 - Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
Experimental: 003 - Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
Experimental: 004 - Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
Experimental: 005 - Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
Placebo comparator: 006 - Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
Treatment: Drugs: Placebo SC
Placebo will be administered subcutaneously.
Treatment: Drugs: Placebo IV
Placebo will be administered as a single Intravenous infusion at week 0.
Treatment: Drugs: Ustekinumab 90 mg SC q8w
Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
Treatment: Drugs: Ustekinumab 130 mg IV
Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
Treatment: Drugs: Ustekinumab 90 mg SC q12w
Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Clinical Remission at Week 44
Query!
Assessment method [1]
0
0
Clinical remission at Week 44 was defined as a Crohn's Disease Activity Index (CDAI) score of \<150 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). CDAI was assessed by collecting information on 8 different Crohn's disease-related variables (extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being). A decrease in CDAI over time indicates improvement in disease activity.
Query!
Timepoint [1]
0
0
Week 44
Query!
Secondary outcome [1]
0
0
Number of Participants With Clinical Response at Week 44
Query!
Assessment method [1]
0
0
Clinical response at Week 44 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (\>=) 100 points. Participants with a baseline CDAI score of \> = 220 to less than or equal (\< =) 248 were considered to be in clinical response if a CDAI score of less than (\<) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.
Query!
Timepoint [1]
0
0
Week 44
Query!
Secondary outcome [2]
0
0
Number of Participants in Clinical Remission at Week 44 Among Participants in Clinical Remission to Ustekinumab at Week 0 of Maintenance Study
Query!
Assessment method [2]
0
0
Clinical remission at week 44 was defined as a CDAI score of \< 150 points among participants in clinical remission to ustekinumab at week 0 of maintenance study.
Query!
Timepoint [2]
0
0
Week 44
Query!
Secondary outcome [3]
0
0
Number of Participants With Corticosteroid-free Remission at Week 44
Query!
Assessment method [3]
0
0
Corticosteroid-free remission at Week 44 was defined as a CDAI score of \<150 points without receiving corticosteroids at Week 44.
Query!
Timepoint [3]
0
0
Week 44
Query!
Secondary outcome [4]
0
0
Number of Participants in Clinical Remission at Week 44 in the Subset of Participants Who Were Refractory or Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy
Query!
Assessment method [4]
0
0
Clinical remission at Week 44 was defined as a CDAI score of \<150 points in the subset of participants who were refractory or Intolerant to tumor necrosis factor antagonist therapy.
Query!
Timepoint [4]
0
0
Week 44
Query!
Eligibility
Key inclusion criteria
* Patients who received study agent at the start of study CNTO1275CRD3001 or CNTO1275CRD3002 and completed the Week 8 visit.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
99
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patients who underwent a Crohn's disease-related surgery since the start of induction study CNTO1275CRD3001 or CNTO1275CRD3002
* Patients who started a protocol prohibited medication since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002
* Patients with protocol-specified changes to their concomitant medications due to Crohn's disease (due to lack of efficacy) since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/09/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1282
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Bedford Park
Query!
Recruitment hospital [3]
0
0
- Box Hill
Query!
Recruitment hospital [4]
0
0
- Central Queensland M C
Query!
Recruitment hospital [5]
0
0
- Concord
Query!
Recruitment hospital [6]
0
0
- Garran
Query!
Recruitment hospital [7]
0
0
- Liverpool
Query!
Recruitment hospital [8]
0
0
- Malvern
Query!
Recruitment hospital [9]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Bedford Park
Query!
Recruitment postcode(s) [3]
0
0
- Box Hill
Query!
Recruitment postcode(s) [4]
0
0
- Central Queensland M C
Query!
Recruitment postcode(s) [5]
0
0
- Concord
Query!
Recruitment postcode(s) [6]
0
0
- Garran
Query!
Recruitment postcode(s) [7]
0
0
- Liverpool
Query!
Recruitment postcode(s) [8]
0
0
- Malvern
Query!
Recruitment postcode(s) [9]
0
0
- Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nevada
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Hampshire
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Jersey
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Ohio
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oklahoma
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oregon
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Pennsylvania
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
South Carolina
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Tennessee
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Texas
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Utah
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Wisconsin
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Innsbruck
Query!
Country [36]
0
0
Austria
Query!
State/province [36]
0
0
Wien
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Brussel
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Leuven
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Liege
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Goiânia
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Porto Alegre
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Rio de Janeiro
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
São Paulo
Query!
Country [44]
0
0
Bulgaria
Query!
State/province [44]
0
0
Pleven
Query!
Country [45]
0
0
Bulgaria
Query!
State/province [45]
0
0
Rousse
Query!
Country [46]
0
0
Bulgaria
Query!
State/province [46]
0
0
Sofia
Query!
Country [47]
0
0
Bulgaria
Query!
State/province [47]
0
0
Varna
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Alberta
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
British Columbia
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Manitoba
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Ontario
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Quebec
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Saskatchewan
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Winnipeg
Query!
Country [55]
0
0
Croatia
Query!
State/province [55]
0
0
Rijeka
Query!
Country [56]
0
0
Croatia
Query!
State/province [56]
0
0
Zagreb
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Hradec Kralove
Query!
Country [58]
0
0
Czechia
Query!
State/province [58]
0
0
Usti nad Labem
Query!
Country [59]
0
0
Denmark
Query!
State/province [59]
0
0
Herlev
Query!
Country [60]
0
0
Denmark
Query!
State/province [60]
0
0
Silkeborg
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Lille
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Marseille
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Paris
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Pessac
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Reims
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Rouen
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Toulouse
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Vandoeuvre les Nancy
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Berlin
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Erlangen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Frankfurt
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Freiburg
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Halle
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Hamburg
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Hannover
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Haßloch
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Heidelberg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Jena
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Kiel
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
LÿNEBURG
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Mannheim
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
München
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Münster
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Regensburg
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Stade
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Ulm
Query!
Country [87]
0
0
Hungary
Query!
State/province [87]
0
0
Budapest
Query!
Country [88]
0
0
Hungary
Query!
State/province [88]
0
0
Békéscsaba
Query!
Country [89]
0
0
Hungary
Query!
State/province [89]
0
0
Debrecen
Query!
Country [90]
0
0
Hungary
Query!
State/province [90]
0
0
Mosonmagyarovar
Query!
Country [91]
0
0
Hungary
Query!
State/province [91]
0
0
Pecs
Query!
Country [92]
0
0
Hungary
Query!
State/province [92]
0
0
Szekesfehervar
Query!
Country [93]
0
0
Hungary
Query!
State/province [93]
0
0
Szeksz Rd N/a
Query!
Country [94]
0
0
Iceland
Query!
State/province [94]
0
0
Reykjavik
Query!
Country [95]
0
0
Ireland
Query!
State/province [95]
0
0
Dublin 9
Query!
Country [96]
0
0
Israel
Query!
State/province [96]
0
0
Jerusalem
Query!
Country [97]
0
0
Israel
Query!
State/province [97]
0
0
Kfar Saba
Query!
Country [98]
0
0
Israel
Query!
State/province [98]
0
0
Petah Tikva
Query!
Country [99]
0
0
Israel
Query!
State/province [99]
0
0
Ramat-Gan
Query!
Country [100]
0
0
Israel
Query!
State/province [100]
0
0
Rehovot
Query!
Country [101]
0
0
Israel
Query!
State/province [101]
0
0
Tel Aviv
Query!
Country [102]
0
0
Israel
Query!
State/province [102]
0
0
Zerifin
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Chikushino
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Fukuoka
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Hachioji
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Hamamatsu
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Hirosaki
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Hiroshima
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Kagoshima
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Nishinomiya
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Ohtsu
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Oita
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Osaka
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Sakura
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Sapporo
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Sendai
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Suita-shi
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Tokyo
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Tsu
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Uruma
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Yokkaichi
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Yokohama
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Yokosuka
Query!
Country [124]
0
0
Korea, Republic of
Query!
State/province [124]
0
0
Daegu
Query!
Country [125]
0
0
Korea, Republic of
Query!
State/province [125]
0
0
Gyeonggi-Do
Query!
Country [126]
0
0
Korea, Republic of
Query!
State/province [126]
0
0
Seoul
Query!
Country [127]
0
0
Netherlands
Query!
State/province [127]
0
0
Amsterdam
Query!
Country [128]
0
0
Netherlands
Query!
State/province [128]
0
0
Maastricht
Query!
Country [129]
0
0
Netherlands
Query!
State/province [129]
0
0
Rotterdam
Query!
Country [130]
0
0
New Zealand
Query!
State/province [130]
0
0
Auckland
Query!
Country [131]
0
0
New Zealand
Query!
State/province [131]
0
0
Christchurch
Query!
Country [132]
0
0
New Zealand
Query!
State/province [132]
0
0
Dunedin
Query!
Country [133]
0
0
New Zealand
Query!
State/province [133]
0
0
Grafton
Query!
Country [134]
0
0
New Zealand
Query!
State/province [134]
0
0
Hamilton
Query!
Country [135]
0
0
New Zealand
Query!
State/province [135]
0
0
Hastings
Query!
Country [136]
0
0
New Zealand
Query!
State/province [136]
0
0
Plenty
Query!
Country [137]
0
0
Poland
Query!
State/province [137]
0
0
Elblag
Query!
Country [138]
0
0
Poland
Query!
State/province [138]
0
0
Krakow
Query!
Country [139]
0
0
Poland
Query!
State/province [139]
0
0
Lodz
Query!
Country [140]
0
0
Poland
Query!
State/province [140]
0
0
Warszawa
Query!
Country [141]
0
0
Russian Federation
Query!
State/province [141]
0
0
Moscow
Query!
Country [142]
0
0
Russian Federation
Query!
State/province [142]
0
0
Novosibirsk
Query!
Country [143]
0
0
Russian Federation
Query!
State/province [143]
0
0
Saint-Petersburg
Query!
Country [144]
0
0
Serbia
Query!
State/province [144]
0
0
Belgrade
Query!
Country [145]
0
0
South Africa
Query!
State/province [145]
0
0
Cape Town Western Cape
Query!
Country [146]
0
0
South Africa
Query!
State/province [146]
0
0
Cape Town
Query!
Country [147]
0
0
South Africa
Query!
State/province [147]
0
0
Pretoria
Query!
Country [148]
0
0
South Africa
Query!
State/province [148]
0
0
Somerset West
Query!
Country [149]
0
0
Spain
Query!
State/province [149]
0
0
Madrid
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Birmingham
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Brighton
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Bristol
Query!
Country [153]
0
0
United Kingdom
Query!
State/province [153]
0
0
Cambridge
Query!
Country [154]
0
0
United Kingdom
Query!
State/province [154]
0
0
Cardiff
Query!
Country [155]
0
0
United Kingdom
Query!
State/province [155]
0
0
Exeter
Query!
Country [156]
0
0
United Kingdom
Query!
State/province [156]
0
0
Gloucester
Query!
Country [157]
0
0
United Kingdom
Query!
State/province [157]
0
0
Liverpool
Query!
Country [158]
0
0
United Kingdom
Query!
State/province [158]
0
0
London
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
Manchester
Query!
Country [160]
0
0
United Kingdom
Query!
State/province [160]
0
0
Norwich
Query!
Country [161]
0
0
United Kingdom
Query!
State/province [161]
0
0
Nottinghamshirecc
Query!
Country [162]
0
0
United Kingdom
Query!
State/province [162]
0
0
Oxford
Query!
Country [163]
0
0
United Kingdom
Query!
State/province [163]
0
0
Shropshire
Query!
Country [164]
0
0
United Kingdom
Query!
State/province [164]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01369355
Query!
Trial related presentations / publications
Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022 Oct;44(10):1336-1355. doi: 10.1016/j.clinthera.2022.08.010. Epub 2022 Sep 21. Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterol J. 2021 Jun;9(5):581-589. doi: 10.1002/ueg2.12094. Epub 2021 Jun 2. Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG, Lynch JP. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. doi: 10.1016/j.cgh.2021.02.025. Epub 2021 Feb 19. Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm Bowel Dis. 2021 Jun 15;27(7):994-1007. doi: 10.1093/ibd/izaa236. Erratum In: Inflamm Bowel Dis. 2021 Jun 15;27(7):1175. doi: 10.1093/ibd/izab014. Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology. 2019 Oct;157(4):1019-1031.e7. doi: 10.1053/j.gastro.2019.06.037. Epub 2019 Jul 4. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 1;14(1):23-32. doi: 10.1093/ecco-jcc/jjz110. Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf. 2019 Jun;42(6):751-768. doi: 10.1007/s40264-019-00797-3. Erratum In: Drug Saf. 2019 Jun;42(6):809. doi: 10.1007/s40264-019-00816-3. Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29. Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 May;154(6):1660-1671. doi: 10.1053/j.gastro.2018.01.043. Epub 2018 Feb 1. Hibi T, Imai Y, Murata Y, Matsushima N, Zheng R, Gasink C. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intest Res. 2017 Oct;15(4):475-486. doi: 10.5217/ir.2017.15.4.475. Epub 2017 Oct 23. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI-IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01369355
Download to PDF